Sleepiness and fatigue are the most common complaints of people with epilepsy and can have a negative impact on quality of life. Though unproven, these problems are often blamed on anti-seizure medications. Cleveland Clinic investigators are studying the impact of the newest anti-seizure medication Lacosamide (Vimpat®) on sleep and wakefulness in adults with focal (partial onset) seizures.
Focal epilepsy, also called partial epilepsy, is a disorder in which seizures are preceded by an isolated disturbance such as a twitching of a part of the body, a particular sensation or feeling, or some other disturbance in consciousness. The study is open to adults 18 and older with focal seizures.
Participation involves a physical exam, sleep testing at the Sleep Center, blood tests, completion of study questionnaires/diaries, and a random assignment to either take the study drug or placebo (often called a “look alike” or “sugar pill”) for 5 to 8 weeks. There are 5 study visits and participants will receive compensation for time spent in the study.
If you would like more information on this study please contact:
Nancy Foldvary-Schaefer, DO, Cleveland Clinic Sleep Disorders Center at 216.445.2990, or
Monica Bruton, Study Coordinator at 216.444.6718